Evaluation of Symptom Benefit Rate of Trabectedin/PLD in Patients With Recurrent Ovarian Cancer
- Status
- TERMINATED
- Phase
- PHASE3
Clinical Trials Related to Bevacizumab
Related studies linked through entity extraction aliases.
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent Glioblastoma
- Status
- COMPLETED
- Phase
- PHASE2
Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors
- Status
- UNKNOWN
- Phase
- PHASE2
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)
- Status
- COMPLETED
- Phase
- PHASE3
A Study of the Efficacy and Safety of Bevacizumab in Chinese Women With Newly Diagnosed, Previously Untreated Stage III or Stage IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- COMPLETED
- Phase
- PHASE3
Study to Evaluate the Efficacy of FOLFOX + Panitumumab Followed by FOLFIRI + Bevacizumab (Sequence 1) Versus FOLFOX + Bevacizumab Followed by FOLFIRI + Panitumumab (Sequence 2) in Untreated Patients With Wild-type RAS Metastatic, Primary Left-sided, Unresectable Colorectal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma
- Status
- UNKNOWN
- Phase
- PHASE1
Atezolizumab Monotherapy and Consequent Therapy With Atezolizumab Plus Bevacizumab for NSCLC
- Status
- UNKNOWN
- Phase
- PHASE2
Upfront Treatment With Chemotherapy and Bevacizumab in Advanced Ovarian Cancer
- Status
- UNKNOWN
- Phase
- PHASE2
A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies
- Status
- UNKNOWN
- Phase
- PHASE1/PHASE2
A Study of RGX-202-01 (Ompenaclid) as Combination Therapy in RAS Mutant Advanced Colorectal Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Pembrolizumab in Combination with Bevacizumab and Pegylated Liposomal Doxorubicin in Patients with Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE1
Bevacizumab and Anetumab Ravtansine or Paclitaxel in Treating Patients With Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
QUILT-3.080: NANT Pancreatic Cancer Vaccine
- Status
- TERMINATED
- Phase
- PHASE1/PHASE2
Effect of Bevacizumab in Metastatic Triple Negative Breast Cancer
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Compare the Pharmacokinetics of JHL1149 and Bevacizumab (Avastin) in Healthy Male Volunteers
- Status
- COMPLETED
- Phase
- PHASE1
A Study to Evaluate the Efficacy and Safety of Novel Treatment Combinations in Participants With Ovarian Cancer
- Status
- COMPLETED
- Phase
- PHASE2
Pilot Study of 18F-FMISO PET/CT and MRI Imaging to Explore Tissue Hypoxia and Arteriovenous Shunting in Subjects With Recurrent Glioblastoma Before and After Bevacizumab Treatment
- Status
- TERMINATED
- Phase
- PHASE1
QUILT-3.088: NANT Pancreatic Cancer Vaccine
- Status
- WITHDRAWN
- Phase
- PHASE2
Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix
- Status
- COMPLETED
- Phase
- PHASE3